Forte Biosciences seeks Nasdaq delisting, plans to end SEC reporting after merger closes
Reuters2026/08/27 20:16- Forte Biosciences requested Nasdaq suspend trading and delist its shares following completion of its merger on Aug. 27, 2026.
- Nasdaq is expected to file Form 25 to remove the stock from listing and deregister it under Exchange Act Section 12(b).
- A Form 15 filing is planned to terminate registration under Section 12(g) and suspend SEC reporting duties under Sections 13 and 15(d).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Orora names Susannah Jobling Hodgens chief legal officer, company secretary successor
AirAsia says drug tests for all active pilots, cabin crew return negative results
GE HealthCare (GEHC.US) plans to acquire Sofie for $1 billion, aiming for high growth in the radiopharmaceutical sector
GE Healthcare plans to acquire Sofie for about $1 billion, aiming to expand recurring revenue by combining imaging devices with radiodiagnostic agents, in response to weak stock performance and pressure from activist investors.
Silver Price Forecast: XAG/USD bears have the upper hand below $64.75-$64.85 confluence
Crypto prices
More
